Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,47 MB, PDF-dokument

  • Amber A. DeVries
  • Joe Dennis
  • Jonathan P. Tyrer
  • Pei-Chen Peng
  • Simon G. Coetzee
  • Alberto L. Reyes
  • Jasmine T. Plummer
  • Brian D. Davis
  • Stephanie S. Chen
  • Felipe Segato Dezem
  • Katja K. H. Aben
  • Hoda Anton-Culver
  • Natalia N. Antonenkova
  • Matthias W. Beckmann
  • Alicia Beeghly-Fadiel
  • Andrew Berchuck
  • Natalia Bogdanova
  • Nadja Bogdanova-Markov
  • James D. Brenton
  • Ralf Butzow
  • Ian Campbell
  • Jenny Chang-Claude
  • Georgia Chenevix-Trench
  • Linda S. Cook
  • Anna DeFazio
  • Jennifer A. Doherty
  • Thilo Dork
  • Diana M. Eccles
  • A. Heather Eliassen
  • Peter A. Fasching
  • Renee T. Fortner
  • Graham G. Giles
  • Ellen L. Goode
  • Marc T. Goodman
  • Jacek Gronwald
  • Niclas Hakansson
  • Michelle A. T. Hildebrandt
  • Chad Huff
  • David G. Huntsman
  • Allan Jensen
  • Siddhartha Kar
  • Beth Y. Karlan
  • Elza K. Khusnutdinova
  • Lambertus A. Kiemeney
  • Kjær, Susanne Krüger
  • Jolanta Kupryjanczyk
  • Marilyne Labrie
  • Diether Lambrechts
  • Nhu D. Le
  • Jan Lubinski
  • OPAL Study Grp
  • AOCS Grp

Background Known risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort. Methods Single nucleotide polymorphism array data from 13 071 EOC cases and 17 306 controls of White European ancestry were used to identify CNVs associated with EOC risk using a rare admixture maximum likelihood test for gene burden and a by-probe ratio test. We performed enrichment analysis of CNVs at known EOC risk loci and functional biofeatures in ovarian cancer-related cell types. Results We identified statistically significant risk associations with CNVs at known EOC risk genes; BRCA1 (P-EOC = 1.60E-21; OREOC = 8.24), RAD51C (Phigh-grade serous ovarian cancer [HGSOC] = 5.5E-4; odds ratio [OR](HGSOC) = 5.74 del), and BRCA2 (P-HGSOC = 7.0E-4; ORHGSOC = 3.31 deletion). Four suggestive associations (P < .001) were identified for rare CNVs. Risk-associated CNVs were enriched (P < .05) at known EOC risk loci identified by genome-wide association study. Noncoding CNVs were enriched in active promoters and insulators in EOC-related cell types. Conclusions CNVs in BRCA1 have been previously reported in smaller studies, but their observed frequency in this large population-based cohort, along with the CNVs observed at BRCA2 and RAD51C gene loci in EOC cases, suggests that these CNVs are potentially pathogenic and may contribute to the spectrum of disease-causing mutations in these genes. CNVs are likely to occur in a wider set of susceptibility regions, with potential implications for clinical genetic testing and disease prevention.

OriginalsprogEngelsk
TidsskriftJournal of the National Cancer Institute
Vol/bind114
Udgave nummer11
Sider (fra-til)1533–1544
Antal sider12
ISSN0027-8874
DOI
StatusUdgivet - 2022

ID: 323204024